Stay up to date with news and events
Hunting for balance: how the huntingtin protein compensates in HD
April 6, 2023
A group led by Dr. Sandrine Humbert from the French National Institute for Health and Medical Research published new work in the prestigious journal Science….
Roche Phase II GENERATION HD2 study underway
February 16, 2023
Roche released a community letter last month, detailing how their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. Learn more…
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
December 9, 2022
The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment…
uniQure gets the green light to resume testing HD gene therapy
November 5, 2022
In August 2022, uniQure announced a pause in new recruitment for their trial of AMT-130, an HD gene therapy delivered via brain surgery. The decision…
Update on the PTC Therapeutics PIVOT-HD Trial
November 4, 2022
Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of…